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Objective. To evaluate the feasibility of a telemedicine system based on Internet and a short message service in pregnancy and its
inﬂuenceondeliveryandneonataloutcomesofwomenwithgestationaldiabetesmellitus(GDM). Methods.100womendiagnosed
of GDM were randomized into two parallel groups, a control group based on traditional face-to-face outpatient clinic visits and
an intervention group, which was provided with a Telemedicine system for the transmission of capillary glucose data and short
text messages with weekly professional feedback. 97 women completed the study (48/49, resp.). Main Outcomes Measured.T h e
percentage of women achieving HbA1c values <5.8%, normal vaginal delivery and having a large for-gestational-age newborn
were evaluated. Results. Despite a signiﬁcant reduction in outpatient clinic visits in the experimental group, particularly in insulin-
treated women (2.4 versus 4.6 hours per insulin-treated woman resp.; P<. 001), no signiﬁcant diﬀerences were found between
the experimental and traditional groups regarding HbA1c levels (all women had HbA1c <5.8% during pregnancy), normal
vaginal delivery (40.8% versus 54.2%, resp.; P>. 05) and large-for-gestational-age newborns (6.1% versus 8.3%, resp.; P>. 05).
Conclusions. The system signiﬁcantly reduces the need for outpatient clinic visits and achieves similar pregnancy, delivery, and
newborn outcomes.
1.Introduction
Many studies indicate that the complications of diabetes may
be prevented through tight metabolic control and accurate
patient monitoring [1, 2] .T h ea c t i v ei n v o l v e m e n to ft h e
patientinhis/hermanagementisessentialtooptimizeresults
and can only be achieved if ﬂuid and regular communication
circuits are established between the patient and the health-
care providers. Traditional methods of communication via
physicalattendanceofthepatientatoutpatientclinicscannot
easily attain the needed level of feedback and interchange.
Furthermore, the growing prevalence of diabetes makes this
optimal level of assistance diﬃcult to implement in clinical
practice, given the limited health system resources available,
as well as the interference that intensive follow-up can have
with the working life of patients.
Telemedicine-based systems have been increasingly used
over the last decade to facilitate the monitoring of diabetes
[3–5]. Diﬀerent services have been designed, with varied
levels of complexity, in accordance with the evolution of
technology and communications engineering [6–8]. These
systems are primarily designed to provide a tool to improve
thequalityofcarethroughaclosercommunicationsnetwork
between the patient and the professional. Moreover, they
attempt to create a more dynamic and motivating commu-
nication, involving the patients to a greater extent in their
own care and making the monitoring of the disease more
compatible with patients’ lifestyles [6–12].
Women with gestational diabetes mellitus (GDM)
require frequent changes in treatment and constant feedback
from healthcare providers. During the short period of time
up to child birth, the patient has to make important changes2 International Journal of Endocrinology
in nutritional habits and physicalactivity, undergo strict self-
monitoring of capillary blood glucose, and, in some cases,
must start using insulin.
In our health area, immigration has meant a sharp
increase in the number of patients with gestational diabetes,
and new strategies are needed to attend these patients and
avoid massiﬁcation of our outpatient clinics. Our group has
previously reported [13] that a telemedicine system may
be used safely by women with GDM. The objective of this
study is to report pregnancy, delivery, and newborn data and
outcomes of women with GDM when treated using a ﬂuid
telemedicine system as compared with standard outpatient
clinic care.
2.Subjects,Materials,andMethods
2.1. Patients. We designed a prospective, randomized, clinic-
based, and interventional study with two parallel groups.
Eligible women diagnosed as having GDM (Carpenter-
Coustan criteria) before 28 weeks of gestation and referred
to the Unit of Gestational Diabetes of the Hospital Cl´ ınico
Universitario San Carlos (HCSC) of Madrid, Spain, from
June to December 2007 were invited to participate in the
study. Sixteen women were excluded, 10 with inability to
understand or to comply with the protocol and 6 women
refused to participate. A total of 100 women gave their
written informed consent and were allocated either to the
intervention group (A, n=50), provided with a telemedicine
system detailed below, or allocated to the control group (B,
n=50) that was treated in accordance with our standard
face-to-face monitoring outpatient protocol. Patients were
followed until delivery. 97 women completed the study (48
from group A and 49 from group B, resp.). The study was
approved by the Ethical Committee of the Hospital Cl´ ınico
Universitario San Carlos and was carried out in accordance
with the principles expressed in the Helsinki Declaration.
Clinical characteristics are displayed in Table 1.
2.2. Experimental Design. At visit 0 (between 24–28 weeks
of pregnancy), patient data were collected: age, nationality,
educational level, employment status, problems in access to
the medical center, family history, personal history (hyper-
tension, smoking status, obesity, thyroidal disease, and other
comorbidities), obstetric history (number of pregnancies,
miscarriages, and gestational diabetes in previous pregnan-
cies), use of medications, and body weight and height.
Patients were instructed by the nurse educator in
nutritional habits and self-monitoring of capillary blood
glucose and informed about the goals of glycemic control:
fasting and preprandial blood glucose <95mg/dl and 1-hour
postprandial blood glucose <120mg/dl. Body weight, blood
pressure, HbA1c, and ﬁrst morning urine sample albumin-
to-creatinine ratio were assessed.
At visit 1, one week later (before 28 weeks gestation),
capillary blood glucose values were evaluated. Six capillary
blood glucose determinations a day were recommended
during the ﬁrst week. If more than 4 of 5 fasting and
premeal glycemic values were <95mg/dl in the ﬁrst week,
Table 1: Characteristics of the survey population by groups.
Control Telemedicine P
N 48 49
Age (years) 34.19 ± 5.18 33.33 ± 5.58 .357
Race/Ethnicity
.608
Caucasian 27 (56.3%) 25 (51%)
Hispanic 18 (37.5%) 15 (30.6%)
Asian 2 (4.2%) 3 (6.1%)
North African 1 (2.1%) 2 (4.1%)
Others 0( 0 % ) 4( 8 . 2 % )
Education
.188
Below high school 9 (18.8%) 8 (16.3%)
Some high school 12 (25%) 5 (10.2%)
High school graduate 9 (18.8%) 14 (28.6%)
College or above 6 (12.5%) 9 (18.4%)
Unknown 12 (25%) 13 (26.5%)
EMPLOYMENT 28 (58.3%) 27 (55.1) .371
Access problems to oﬃce 31 (64.6%) 28 (57.1%) .490
Family history of
Diabetes
23 (47.9%) 23 (46.9%) .494
Number of pregnancies 2.48 ± 1.51 2.06 ± 1.36
.162 Primiparous 12 (25%) 18 (38.3%)
Second pregnancy 19 (39.6%) 19 (40.4%)
>2 pregnancies 17 (35.4%) 10 (21.3%)
MISCARRIAGE 19 (39.6%) 13 (26.5%) .215
Prior GDM 9 (18.8%) 4 (8.2%) .104
Hypertension 5 (10.4%) 4 (8.2%) .590
Thyroid disease 7 (14.6%) 8 (16.3%) .361
Current smoker 2 (4.2%) 3 (6.1%) .081
HbA1c at entry (%) 5.10 ± 0.41 5.03 ± 0.38 .164
Prepregnancy body
weight (kg)
74.06 ± 15.37 70.46 ± 12.98 .470
Prepregnancy BMI
(kg/m2)
29.01 ± 5.74 27.96 ± 5.24 .588
Data are Mean ± SDM or n (%).
GDM denotes Gestational Diabetes Mellitus; BMI: Body Mass Index.
only 1 hour postmeal capillary blood glucose determinations
were recommended daily or every other day until delivery.
The 8 women most likely to require insulin after the
evaluationoftheﬁrst7daysofbloodglucoseproﬁles(atleast
50% of postmeals blood glucose values >115mg/dl) were
allocated to the telemedicine group, because this subgroup
of patients was expected to need more provider contacts and
therefore beneﬁt more from the telemedicine system.
The remaining 92 women were randomized into two
groups (control and intervention), according to age and
obstetric history.
During the follow-up of both groups, 4 face-to-face visits
(oneamonth)werescheduleduntildelivery(before28weeks
of gestation (visit 1), and between 32–34 (visit 2), 36–38
(visit 3), and 39-40 weeks (visit 4)). Body weight, blood
pressure, HbA1c, and ﬁrst morning urine sample albumin-
to-creatinine ratio were determined in each visit. CapillaryInternational Journal of Endocrinology 3
Table 2: Maternal Metabolic parameters during gestation.
Control
group
Telemedicine
group
sBP (mm Hg)
Visit 1 122.0 ± 16.8 122.3 ± 12.5
Visit 2 122.3 ± 14.5 120.8 ± 11.1
Visit 3 121.9 ± 13,2 125.1 ± 9.8
Visit 4 120.8 ± 14.8 122.9 ± 10.8
dBP (mm Hg)
Visit 1 71.5 ± 8.6 72.6 ± 9.5
Visit 2 71.4 ± 8.6 72.8 ± 5.6
Visit 3 72.3 ± 9.1 74.6 ± 8.9
Visit 4 72.1 ± 8.0 76.8 ± 10.6
HbA1c (%)
Visit 1 5.2 ± 0.4 5.0 ± 0.4
Visit 2 5.2 ± 0.4 5.0 ± 0.3
Visit 3 5.3 ± 0.4 5.2 ± 0.4
Visit 4 5.4 ± 0.4 5.3 ± 0.4
Albumin-to-creatinine
Ratio (mg/g)
Visit 1 6.8 ±4.9 10.1 ±14.4
Visit 2 6.4 ± 3.8 7.8 ± 5.6
Visit 3 8.2 ± 7.9 10.0 ± 8.6
Visit 4 5.1 ± 2.9 7.7 ± 5.3
Body Weight (Kg)
Visit 1 76.9 ± 14.3 75.9 ± 13.2
Visit 2 77.9 ± 14.8 76.8 ± 11.8
Visit 3 78.6 ± 15.8 77.8 ± 12.9
Visit 4 82.3 ± 16.3 80.7 ± 14.7
Weight Gain (Kg) Visit 1–4 6.446 ± 4.988 5.822 ± 3.950
Insulin-treated Women n
(%) 9 (18.8%) 17
(34.7%)
Total contact per
Insulin-treated women
(total hours)
9.11 (4.6) 15.05
(3.8)∗∗∗
Data expressed as mean + SDM. sBP, systolic blood pressure. dBP, diastolic
blood pressure. ACR, ﬁrst morning urine sample albumin-to-creatinine
ratio.
∗∗∗P<. 001.
glucose values recorded by the patient in her logbook were
evaluated, and episodes of mild or severe hypoglycaemia and
insulin requirements were registered.
Patients in the control group were followed according
to protocol for gestational diabetes at HCSC, including the
same capillary blood glucose targets, and were given the
opportunity to attend the outpatient clinic without prior
appointment(nonscheduledvisit)andbringintheirlogbook
when their blood glucose values were above the objectives
or for any queries regarding nutritional recommendations
or insulin dose. The total number of patients’ nonscheduled
visitstothemedicalcentre,lossofworkdays,andthenumber
of hospital admissions were regularly recorded.
2.3. Telemedicine System. The telemedicine system consists
of a central database and peripheral units, with cellular
phones and a Glucometer capable of transmitting data via
infrared port.
Each woman in the intervention group received a Glu-
cometer (Accu-Chek Compact Plus) with a cellular phone
(Nokia E50-1), the latter with a preinstalled application
that allows the transmission of capillary glucose values to
the central database via short message service (SMS). This
application has also an interface that allows the infrared
transmission of the glucose values stored in the glucometer
to the cellular phone. The system enables the patient to
regularly transmit blood glucose values and also to maintain
contactthroughshorttextmessageswithhealthprofessionals
as required.
Patients wererecommended tosendblood glucosevalues
recorded in the glucometer to the medical terminal once a
week.
An endocrinologist and a diabetes nurse educator eval-
uated patients’ data accessing into the Emminens Conecta
Plus Web Application (http://www.emminens.com/)f r o m
any PC with Internet connection. Entering a personal
password, they had access to blood glucose values sent by
the patients, accompanied by their identiﬁcation by patients’
initials, date and time of measurement. The application
provides graphics showing glycemic trends over time, charts
ofeverydayandweeklyglucosevalues,andthedailyglycemic
values of every patient. Health professionals can send text
messages from their computer, and they are received via
Internet on the cellular phone of the patient. Through
these messages, the professional makes recommendations
for nutritional changes or adjustments in insulin doses.
Patients can send text messages from their cellular phones
to the medical terminal via Internet with questions as
requiredoranswerquestionsabouttheirnutritional patterns
or treatment. Our group previously reported that this
telemedicinesystemmaybeusedsafelybywomenwithGDM
[13].
2.4. Statistical Analysis. Sample size was estimated to test the
hypothesis that the telemedicine-based intervention would
not be inferior to standard therapy. A primary endpoint
diﬀerence was detecting more than a 20% diﬀerence in
HbA1c of patients achieving HbA1c values <5.8%. With 40
patients in each group, the study had 80% power to detect a
20% diﬀerence between groups at 5% signiﬁcance.
The statistical study was performed by using SPSS 15.0
program for Windows. Descriptive data are expressed as
median and Q1-Q3 or mean ± SDM. Nonparametric Mann-
Whitney and Kruskal-Wallis tests were carried out to detect
signiﬁcant diﬀerences between groups.
3. Results
There was a signiﬁcant 62% reduction in outpatient clinic
visits in women from the telemedicine group. This reduc-
tion was even greater in the case of the insulin-treated
women of the group, with a 82% reduction of outpatient
women (P<. 03) as compared with those patients who
exclusively assisted in the outpatient clinic setting. Women
from the telemedicine group achieved similar HbA1c values
(all <5.8%), systolic and diastolic blood pressure values,
albumin-to-creatinine ratio, and weight gain (5.820 + 3.950
versus 6.446 + 4.988Kg; P>. 05) as the control patients.
The average total number of outpatient clinic visits was 9.114 International Journal of Endocrinology
Table 3: Gestation, Delivery and New Born data.
Control group Telemedicine
group P
N4 8 4 9
Gestational Weeks at
Delivery 39.42 ± 1.42 39.12 ± 1.66 n.s.
Pregnancy induced
hypertension 0 (0%) 2 (4.1%) .501
Delivery Outcomes
Normal vaginal birth 26 (54.2%) 20 (40.8%) .068
Dystocia 17 (35.4%) 27 (55.1%)
(i) Caesarean Section 12 (25%) 17 (34.7%) .427
(ii) Instrumental vaginal
birth 5 (10.4%) 10 (20.4%)
New born gender (M/F) 22 (47.9%)/18
(37.5%)
20 (40.8%)/26
(53.1%) .240
Birth weight (g) 3370.6 ± 479.1 3308.2 ± 488.8
.385 (i) Male 3407.1 ± 492.2 3214.5 ± 435.7
(ii) Female 3346.9 ± 481.3 3380.2 ± 522.9
New born Outcomes
.500
Large-for-gestational age 4 (8.3%) 3 (6.1%)
Hypoglycemia 0 (0%) 1 (2%)
Hypokaliemia 0 0
Hypocalcemia 0 0
Poliglobulia 0 0
Small-for-gestational age 0 0
Preterm Birth (GA <37
weeks) 1 (2.1%) 1 (2.0%)
Loss of fetal wellbeing 5 (10.4%) 3 (6.1%)
Umbilical cord pathology 2 (4.2%) 1 (2.0%)
Shoulders dystocia 1 (2.1%) 0 (0%)
Abruptio placentae 1 (2.1%) 0 (0%)
Data are Mean ± SDM or n (%).
for insulin-treated diabetic women in the control group (4.6
hours per woman) as compared to 4.25 for those in the
intervention group (2.37 hours per insulin-treated woman).
In addition to the outpatient clinic visits, insulin-treated
women from the intervention group had an additional
10.8 contacts on average (1.44 hours per insulin-treated
woman). In other words, the women in the intervention
group had more contacts with health personnel (15.05
versus 9.11) taking up less time (3.8 versus 4.6 hours;
P<. 001) than the control group. Data are displayed in
Table 2. Pregnancy-induced hypertension was observed in
2 women from the telemedicine group. Normal vaginal
birth rate (20 (40.8%) versus 26 (54.2%), resp.; P<. 068)
and the frequency of caesarean section (17 (34.7%) versus
12 (25%), resp.; P>. 05) were similar in both groups
3 (6.1%) and 4 (8.3%). A similar percentage of neonates
were large for gestational age in both groups (6,1 and 8,3
% resp.). Data are displayed in Table 3. We did not detect
diﬀerences in clinical and laboratory data during the follow-
up nor were diﬀerences in delivery and neonatal outcomes
observed.
4. Discussion
The present study shows that a telemedicine system can be
useful as an alternative to traditional outpatient clinic visits.
Although women in the telemedicine group attended the
outpatient clinic less frequently than those in the control
group, we found no deleterious eﬀects on metabolic control,
pregnancy, delivery, or on the newborn despite the presence
of a higher proportion of insulin-using patients in the
telemedicine group.
A reduction in the number of clinic visits saves time
of both the patient and the health professional, and the
telemedicine connection increases patient accessibility to
the professional team, permitting contact at the women’s
convenience. Needless to say, telemedicine communications
facilitate patients’ lives, reducing transportation and outpa-
tient waiting times and minimizing interfere with patients’
regular work schedules. The telemedicine system was par-
ticularly useful in the subgroup of insulin-treated patients,
who require more contacts to adjust the insulin dose. The
extent of the use of the telemedicine system has been variable
and is highly dependent on the woman’s cultural level [13].
However, in our study, cultural level was similar in both
groups. Atvisit 1, allthe patients assigned to theintervention
group received information about the system and were asked
to send capillary blood glucose values at least once a week.
Access to a computer was not required in order to do so.
Some women in the intervention group, particularly those
with a lower cultural level, preferred directly attending the
outpatient clinic or the use of a landline phone for questions
they considered important.
The professional team also made use of land phones at
certain times, particularly upon initiation of insulinization
or when correct patient compliance was in doubt. But
most treatment decisions involving control of glycemia after
initiation of insulin therapy did not require outpatient clinic
attendance.Insulindoseadjustmentcanbebasedonthedata
ofhomebloodglucosemonitoringeach5proﬁles(3outof5,
1 hour post meal values >120 mg/dl), as used in our study).
Therefore doses could be adjusted every 5 days.
The median outpatient visit duration was 30 minutes
whereas the telematic visit lasted less than 8 minutes,
including assessment of capillary blood glucose proﬁles and
SMS response. In our study, the telemedicine system not
only made attention more convenient for the patient, it was
also was less expensive for the health system in terms of
use of health professionals’ time. Similarly others studies
[14–17] on women from the telemedicine group indicate
a higher level of adherence to treatment and increased
satisfaction.
Although the telemedicine group had a higher rate of
C-sections, this diﬀerence was no signiﬁcant. Furthermore,
there was no between-group diﬀerence in metabolic control,
pregnancy duration, fetal outcome, or neonatal morbidity.
In addition, gestational week at delivery, preterm birth,
fetal macrosomia, and neonatal morbidity were similar to
mothers with normal glucose tolerance during pregnancy in
our hospital. These data suggest that the algorithms used in
thestudyformanagementofgestationaldiabetesmellitusareInternational Journal of Endocrinology 5
useful in order to reach similar outcomes of pregnancy of
women without gestational diabetes mellitus.
Despite the potential beneﬁts, the use of telemedicine
is still very limited and is not integrated into healthcare
systems. There are a few small-scale projects designed to
study the usefulness of telemedicine in patients with GDM
[18–20]. The Commission of the European Communities
recently has written a recommendation [21]t oe n c o u r a g e
Member States in an eﬀort to integrate these new services
into healthcare systems, focusing on improving the con-
ﬁdence and acceptance of telemedicine services through
consistent studies of eﬀectiveness and cost-eﬀectiveness, as
well as bringing legal clarity, solving technical issues, and
facilitating market development, promoting the interoper-
ability of the systems, and improving their quality and
safety.
We conclude that a telemedicine system can be a useful
tool in the treatment of gestational diabetes patients, as a
complement to conventional outpatient clinic visits, espe-
cially in cases requiring tighter glycemic control or with
diﬃculties in access to the medical centre [22].
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